SEED Therapeutics, a BeyondSpring (BYSI) subsidiary, announced that it has appointed Jackson Tai to its Board of Directors. Tai has most recently retired, or will soon retire, as a Non-Executive Director of Eli Lilly (LLY). He brings almost 50 years’ experience in finance, strategy, and risk governance to the SEED Therapeutics Board.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BYSI: